Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group

• Published in: Journal of geriatric oncology Vol. 12; no. 3; pp. 410 - 415
• Main Authors: Arias Ron, David, Areses Manrique, Maria Carmen, Mosquera Martínez, Joaquín, García González, Jorge, Afonso Afonso, Francisco Javier, Lázaro Quintela, Martín, Fernández Núñez, Natalia, Azpitarte Raposeiras, Cristina, Amenedo Gancedo, Margarita, Santomé Couto, Lucía, García Campelo, María Rosario, Muñoz Iglesias, Jose, Ruiz Bañobre, Juan, Vilchez Simo, Rocío, Casal Rubio, Joaquín, Campos Balea, Begoña, Carou Frieiro, Iria, Alonso-Jaudenes Curbera, Guillermo, Anido Herranz, Urbano, García Mata, Jesús, Fírvida Pérez, Jose Luis
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.04.2021
• Subjects: Lung cancer; Nivolumab; Older patients; Pretreated; Real world data; PR; PS; AE; NSCLC; OS; Lung cancer; CI; SIOG; HR; Pretreated; CR; QoL; CT; SD; PD; Nivolumab; TPS; Older patients; Real world data; PFS; RWD
• ISSN: 1879-4068; 1879-4076
• DOI: 10.1016/j.jgo.2020.11.010

Nivolumab is an anti PD1 immunotherapy drug approved for advanced Non-Small Cell Lung Cancer (NSCLC) patients who previously received at least one prior line of treatment. Older patients are often not represented in clinical trials and drugs with acceptable safety profiles are necessary. We aim to report the efficacy and safety profile of Nivolumab in the real-world older subgroup of the Galician lung cancer group study. We retrospectively reviewed 188 advanced NSCLC patients treated with at least one prior therapy. We collected data from patients who were ≥70 years old treated with Nivolumab in second or subsequent lines. Patient characteristics, treatment efficacy (overall survival, progression-free survival, and response rate), and safety profile were reported. Thirty-eight patients aged ≥70 years were included in the subgroup analysis. The median age was 74.5 years, a high percentage of patients were males (95%), most had a Performance Status of 1 (79%) and only 13% were non-smokers. The predominant histology was adenocarcinoma (53%), and 18% of patients received 2 or more lines. The median Progression-Free Survival was 7.53 months (CI 4.3–17.3, p = 0.15) and the median Overall Survival was 14.85 months (CI 10.5–20.7, p = 0.44). The objective response rate was 42%. No new adverse events were reported in comparison to a global population. The efficacy and safety profile of Nivolumab in advanced NSCLC patients treated with at least one prior therapy and age ≥70 years old can be overlapped to a global population. Further prospective trials are needed to define and confirm these results.